MGF and Tendon Research: Mechano Growth Factor Biology, Tenocyte Activation and Tendon Repair Mechanisms UK 2026

This article is intended for research and educational purposes only. MGF (Mechano Growth Factor) and PEG-MGF are Research Use Only (RUO) compounds supplied for laboratory investigation. They are not approved for human use, are not medicines, and must not be administered to humans or animals outside of licenced research settings.

Introduction: MGF as a Tendon Biology Research Tool

Mechano Growth Factor (MGF) is a splice variant of IGF-1 — specifically the Ea splice variant with a 49-bp insert generating the unique MGF E-domain peptide (Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-His-Lys) — produced primarily in response to mechanical loading in muscle, bone, and connective tissue including tendon. MGF’s tendon research significance arises from its expression pattern: mechanical stress to the Achilles tendon, patellar tendon, and rotator cuff tendons upregulates MGF mRNA in tenocytes — the resident fibroblastic cells responsible for ECM production and tendon homeostasis — positioning MGF as an endogenous mechano-responsive anabolic signal in tendon biology research.

This post examines the mechanistic basis for MGF tendon research across tenocyte biology, tendon ECM remodelling, tendinopathy models, and the experimental methodology used to characterise MGF’s effects on connective tissue repair — a research angle distinct from the skeletal muscle and bone biology covered in previously published MGF/PEG-MGF posts.

MGF Expression in Tendon Tissue: Mechanical Regulation

MGF mRNA expression in tendon is mechano-regulated — upregulated by cyclic mechanical strain and downregulated by immobilisation. RT-qPCR quantification of MGF (using primers spanning the unique 49-bp insert junction to distinguish MGF from IGF-1Ea without insert, or from liver-derived IGF-1Eb) in tenocytes isolated from equine superficial digital flexor tendon (SDFT; primary model for athletic tendinopathy), rat Achilles tendon, or human hamstring tendon provides the baseline expression reference.

In vitro mechanical stimulation of tenocytes is achieved by: cyclic equibiaxial strain (10%, 1Hz, 6–24h using Flexcell FX-5000 system with BioFlex collagen-coated plates; cells seeded to 70% confluence before loading); substrate stiffness modulation (polyacrylamide hydrogels 1–40 kPa with fibronectin coating; mechanosensing through integrin-FAK-RhoA-ROCK-YAP/TAZ); and fluid shear stress (parallel-plate flow chamber; 0.5–10 dyn/cm² for 6h). MGF mRNA by RT-qPCR in mechanically stimulated versus static control tenocytes is the primary mechanotransduction endpoint, confirming physiological relevance of exogenous MGF research in the tendon context.

MGF protein secretion from mechanically loaded tenocytes (western blot of conditioned media using anti-MGF E-domain antibody — detecting the unique C-terminal E-peptide rather than the shared N-terminal IGF-1 domain) demonstrates paracrine/autocrine capacity. Blocking autocrine MGF with E-domain-specific antibody during mechanical loading tests whether endogenous MGF contributes to the mechanical anabolic response in tenocyte cultures, providing the in vitro specificity validation for subsequent exogenous MGF experiments.

IGF-1R and MGF E-Domain Receptor Pharmacology in Tenocytes

MGF exerts biological effects through two distinct molecular pharmacologies: the shared N-terminal domain (identical to mature IGF-1 after proteolytic cleavage of the E-domain) activates IGF-1R (IGF-1 receptor; INSR-related RTK) through the canonical Tyr-1135/1136 autophosphorylation-IRS-1-PI3K-Akt-mTORC1 signalling pathway; while the unique MGF C-terminal E-domain peptide (Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-His-Lys; 24 amino acids) acts through a distinct, not yet fully characterised receptor that is not IGF-1R.

In tenocytes, E-domain peptide alone (25-mer synthesised independently) promotes cell survival and proliferation through mechanisms partially independent of IGF-1R — including intracellular Ca²⁺ mobilisation (Fura-2 AM ratiometric imaging), calmodulin-CaMKII activation (western blot for CaMKII Thr-286 autophosphorylation), and ERK1/2 activation without the PI3K-Akt component activated by the N-terminal domain. This pharmacological dissection — E-domain alone vs N-terminal (mature IGF-1) vs full-length MGF — is fundamental to mechanistic tenocyte research design.

IGF-1R expression in tenocytes (RT-PCR, western blot, flow cytometry in primary tenocytes from rat Achilles or equine SDFT) establishes receptor expression context. αIR3 (IGF-1R blocking antibody; 1µg/mL) blocks the N-terminal domain effects; while E-domain effects persist in αIR3-blocked tenocytes, confirming receptor-pharmacology dissociation. Picropodophyllin (PPP; IGF-1R kinase inhibitor; 1µM) and NVP-AEW541 (dual IGF-1R/InsR inhibitor) provide pharmacological IGF-1R blockade alternatives to antibody-based approaches.

Tenocyte Proliferation and Migration Biology

Tenocyte proliferation and migration are central to tendon healing responses — the initial phases of tendon repair after injury require resident tenocyte expansion and migration from uninjured tissue margins into the injury zone. MGF’s proliferative and migratory effects in tenocytes are characterised by parallel in vitro assays:

Proliferation is measured by: MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) colorimetric assay at 24h and 48h (formazan absorbance OD570 proportional to mitochondrial dehydrogenase activity in viable cells); BrdU (5-bromodeoxyuridine) or EdU (5-ethynyl-2′-deoxyuridine) incorporation (2h pulse before fixation; anti-BrdU immunofluorescence or Click-iT EdU fluorescent azide reaction; confocal counting of BrdU+/EdU+ cells per HPF); and Ki-67 immunofluorescence at 48–72h. MGF at 25–200ng/mL produces dose-dependent proliferation enhancement in primary human tenocytes and immortalised human tenocyte (hTERT-immortalised from hamstring tendon; Thorpe et al. characterised model) compared to vehicle control.

Migration is measured by: scratch wound assay (linear scratch in confluent tenocyte monolayer; mitomycin-C 10µg/mL pre-treatment for 2h to inhibit proliferation during migration assay; Fiji wound area measurement at 0, 12, 24h time-lapse); modified Boyden chamber migration (8µm pore PET inserts; tenocytes in serum-free medium in upper chamber; MGF in lower chamber as chemoattractant; 24h migration; calcein-AM staining of migrated cells; fluorescence reading). The distinction between chemokinesis (random motility enhancement) and chemotaxis (directed gradient migration) requires checkerboard analysis.

Tendon ECM Biology: Collagen, Tenascin, and Matrix Remodelling

The tendon ECM is specialised for tensile load transmission: type I collagen (COL1A1/COL1A2) constitutes ~65–80% of dry tendon weight, assembled into hierarchical crimped fibrils → fibres → fascicles → tendon unit. Type III collagen (COL3A1) is elevated in healing and degenerative tendon, reflecting a weaker, more disorganised fibril architecture. Tenascin-C (TNC) is a mechanosensitive glycoprotein upregulated by cyclic strain in tenocytes — serving as a mechanotransduction marker and ECM organiser. Decorin (DCN) and fibromodulin (FMOD) are small leucine-rich proteoglycans that regulate collagen fibril diameter and organisation.

MGF effects on tendon ECM gene expression use primary tenocyte cultures in 3D collagen gel contraction models (type I collagen gel 2mg/mL; cell-seeded at 1×10⁶/mL; 24–48h gel contraction quantified by % area reduction versus initial area in ImageJ) and conventional 2D monolayer cultures. Endpoints include: COL1A1 and COL3A1 mRNA by RT-qPCR (COL1:COL3 ratio as fibril organisation quality marker), tenascin-C mRNA and protein by western blot, decorin and fibromodulin mRNA by qPCR, and secreted collagen by Sircol assay (acidic collagen quantification of conditioned media at 24h and 72h). Collagen fibril organisation in 3D gel models is assessed by second harmonic generation (SHG) microscopy (label-free collagen fibril imaging; fibril orientation quantification by OrientationJ ImageJ plugin), providing nanoscale ECM architecture readouts that complement gene expression data.

MMP/TIMP balance governs tendon ECM remodelling: MMP-1 (collagenase; COL1-specific cleavage), MMP-3 (stromelysin; broad matrix degradation), MMP-13 (collagenase-3; collagen II/III-selective; elevated in tendinopathy), and TIMP-1/TIMP-2 (tissue inhibitors of metalloproteinases). MGF’s effects on MMP/TIMP balance in tenocytes stimulated with IL-1β (10ng/mL; tendinopathy inflammatory model) are assessed by: gelatinase zymography (MMP-2/MMP-9 activity; 10% SDS-PAGE with gelatin substrate; Coomassie-negative bands after renaturation overnight), MMP-1/MMP-3/MMP-13 ELISA from conditioned media (R&D Systems), and TIMP-1/TIMP-2 ELISA — with net protease activity calculated as molar MMP:TIMP ratio.

Tendinopathy Research Models: Collagenase and Needle-Injury

The principal preclinical tendinopathy model uses intratendinous collagenase injection to produce stereotyped degenerative changes — elevated tenocyte density (reactive hypercellularity), disorganised fibril architecture (Bonar histopathological score 0–3; grading collagen fibre disorganisation, cell morphology, and vascularity), neovascularisation (CD31+ vessel density by IHC), and elevated MMP-3/MMP-13 expression — recapitulating histological features of human chronic tendinopathy (Achilles, patellar, supraspinatus).

Collagenase-induced Achilles tendinopathy in rats: 25µL collagenase type I (10mg/mL in PBS) injected into the midsubstance of the Achilles tendon under ultrasound guidance (7.5MHz probe) at day 0. MGF treatment begins at day 3 (post-acute-inflammation) or day 0 (preventive protocol) by intratendinous injection (10–100µg in 10µL PBS) or by systemic s.c. delivery. Assessment at day 7, 14, and 28: Bonar histopathological score (H&E; grading 0–3 for each parameter); Masson trichrome/Sirius Red collagen organisation and COL1:COL3 ratio (confocal polarised light); CD31+ IHC vessel density (neovascularisation resolution); ultrasound tissue characterisation (UTC; echo-type I: bright parallel reflection = organised fibrillar; echo-type II: sub-parallel; echo-type III: irregular; echo-type IV: absent fibrillar; UTC ratio as echo-type I:total cross-sectional pixels); biomechanical testing (Instron 3343; failure load N, stiffness N/mm, elastic modulus MPa; cross-sectional area by calliper or micro-CT for load normalisation).

Needle-injury model (multiple 25-gauge needle passes through tendon midsubstance at day 0) produces a simpler acute repair model without collagenase biochemistry confounding. This model better reflects acute tendon repair biology (post-tenotomy, post-surgery) rather than chronic tendinopathy. Endpoints at day 7 and 14: H&E cellularity and fibril organisation, PCNA+/Ki-67+ tenocyte proliferation IHC, α-SMA myofibroblast IHC (repair phase marker), vimentin (mesenchymal marker; consistent in tenocytes), and biomechanical failure load.

PEG-MGF and Tendon Research: Extended Half-Life Pharmacology

PEG-MGF (polyethylene glycol-conjugated MGF) was developed to extend MGF’s brief plasma half-life (t½ ~2–5 minutes for non-PEGylated MGF due to proteolytic cleavage at the E-domain K/R residues by serum proteases) to approximately 25–30 hours for PEG-MGF, enabling systemic delivery routes rather than repeated local injection. The PEGylation site (N-terminal PEG or lysine-directed PEG attachment) may alter E-domain receptor interactions, making PEG-MGF and non-PEGylated MGF pharmacologically non-identical — a critical distinction for tendon research interpretations.

Comparative PEG-MGF vs MGF studies in collagenase tendinopathy: PEG-MGF at 2mg/kg s.c. 3×/week versus local MGF 100µg per tendon 2×/week allows systemic versus local delivery comparison within the same tendinopathy model. UTC cross-sectional area recovery, Bonar score, and biomechanical failure load at day 28 provide the outcome comparison. Serum MGF/PEG-MGF pharmacokinetics (serial blood collection at 0, 0.5, 1, 2, 4, 8, 24h after administration; anti-MGF E-domain ELISA) confirm the extended half-life and bioavailability profile expected for PEG-MGF.

Mechanotransduction Pathways in MGF-Stimulated Tenocytes: YAP/TAZ Biology

YAP (Yes-associated protein) and TAZ (transcriptional co-activator with PDZ-binding motif; encoded by WWTR1) are mechanosensitive transcriptional co-activators that translocate to the nucleus under high mechanical tension and soft substrate conditions respectively — integrating mechanosensing signals from integrins, focal adhesions, and cytoskeletal tension into gene expression programs controlling proliferation, ECM production, and cell fate. In tenocytes, YAP/TAZ nuclear localisation (stiff substrate, 40kPa hydrogels; high cyclic strain) activates pro-tenogenic and proliferative target genes including tenascin-C, CCN2/CTGF, and ANKRD1.

MGF-E-domain signalling intersects with YAP/TAZ biology through Ca²⁺-CaMKII-mediated LATS1/2 kinase (LATS phosphorylates YAP Ser-127 and Ser-381 to retain YAP in the cytoplasm via 14-3-3 binding) modulation. Research endpoints for YAP/TAZ in MGF-treated tenocytes include: YAP/TAZ nuclear:cytoplasmic ratio by confocal immunofluorescence (anti-YAP antibody; DAPI nuclear mask; fluorescence ratio quantification); YAP Ser-127 phosphorylation by phospho-specific western blot; CTGF and CYR61 mRNA (canonical YAP/TAZ target genes) by qPCR; and YAP/TAZ siRNA knockdown to test whether YAP/TAZ mediates MGF-induced tenascin-C and COL1A1 upregulation.

Experimental Design for MGF Tendon Research

Critical design elements for MGF tendon research: (1) Pharmacological dissection of E-domain versus N-terminal (IGF-1R) effects requires E-domain-only peptide (synthesised separately; 24aa Tyr-Gln-Pro…) versus mature IGF-1 versus full-length MGF versus PEG-MGF — a four-arm comparison establishing which pharmacological component drives each tendon biology endpoint; (2) IGF-1R blocking controls (αIR3 1µg/mL; PPP 1µM) in all MGF experiments to confirm whether IGF-1R-dependent or IGF-1R-independent mechanisms are operative; (3) protease-stability assessment — non-PEGylated MGF degrades within minutes in serum, so in vitro culture medium stability (anti-MGF E-domain ELISA of conditioned medium over 0, 30, 60, 120, 240 minutes) defines the effective concentration-time profile; (4) mechanical loading context — tenocytes cultured under static conditions respond to MGF differently than mechanically loaded cells (Flexcell), since baseline mechanosensing pathway activation state modifies E-domain receptor coupling.

Summary of Key Research Endpoints for MGF Tendon Research

Core MGF tendon research endpoints include: MGF mRNA RT-qPCR 49bp insert junction primers Flexcell 10% 1Hz cyclic strain Fura-2 AM Ca²⁺ CaMKII Thr-286 ERK1/2 αIR3 PPP NVP-AEW541 IGF-1R dissection; MTT BrdU/EdU Ki-67 tenocyte proliferation primary human hTERT-immortalised scratch wound Boyden chemotaxis/chemokinesis checkerboard mitomycin-C; COL1A1-COL3A1-TNC-DCN-FMOD mRNA qPCR Sircol secreted collagen 3D gel contraction % area SHG second harmonic generation fibril orientation OrientationJ; MMP-1-3-13 ELISA TIMP-1-2 molar ratio zymography gelatinase IL-1β 10ng/mL tendinopathy inflammatory model; collagenase 25µL 10mg/mL Achilles midsubstance intratendinous UTC echo-type I:total ratio Bonar H&E score Masson Sirius Red polarised COL1:COL3 CD31+ vessel IHC Instron failure load stiffness elastic modulus cross-sectional area; needle injury 25g multiple passes H&E PCNA α-SMA vimentin; PEG-MGF 2mg/kg s.c. t½ 25-30h vs local MGF 100µg 3×/week pharmacokinetic ELISA comparison; YAP Ser-127 phospho western confocal nuclear:cytoplasmic ratio CTGF CYR61 mRNA siRNA YAP/TAZ mechanosensing; E-domain 24aa Tyr-Gln-Pro mature IGF-1 full-length MGF PEG-MGF four-arm pharmacological dissection; protease stability conditioned medium ELISA 240min degradation profile Flexcell static loading context.